{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:54:30Z","timestamp":1780437270954,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100010166","name":"Xiamen Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","award":["3502Z202372076"],"award-info":[{"award-number":["3502Z202372076"]}],"id":[{"id":"10.13039\/100010166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010166","name":"Xiamen Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","award":["3502Z20227346"],"award-info":[{"award-number":["3502Z20227346"]}],"id":[{"id":"10.13039\/100010166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010166","name":"Xiamen Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","award":["3502Z20224011"],"award-info":[{"award-number":["3502Z20224011"]}],"id":[{"id":"10.13039\/100010166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82100204"],"award-info":[{"award-number":["82100204"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["U22A20290"],"award-info":[{"award-number":["U22A20290"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82470187"],"award-info":[{"award-number":["82470187"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-79173-w","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T13:03:20Z","timestamp":1731330200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Changes of T cell subsets across treatments associated with prognosis in newly diagnosed follicular lymphoma"],"prefix":"10.1038","volume":"14","author":[{"given":"Qiuhui","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongpeng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"79173_CR1","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/ajh.26737","volume":"97","author":"E Jacobsen","year":"2022","unstructured":"Jacobsen, E. Follicular lymphoma: 2023 update on diagnosis and management. Am. J. Hematol. 97, 1638\u20131651. https:\/\/doi.org\/10.1002\/ajh.26737 (2022).","journal-title":"Am. J. Hematol."},{"key":"79173_CR2","doi-asserted-by":"publisher","first-page":"100992","DOI":"10.1016\/j.blre.2022.100992","volume":"57","author":"MJ Gordon","year":"2023","unstructured":"Gordon, M. J., Smith, M. R. & Nastoupil, L. J. Follicular lymphoma: the long and winding road leading to your cure? Blood Rev. 57, 100992. https:\/\/doi.org\/10.1016\/j.blre.2022.100992 (2023).","journal-title":"Blood Rev."},{"key":"79173_CR3","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave, S. S. et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 351, 2159\u20132169. https:\/\/doi.org\/10.1056\/NEJMoa041869 (2004).","journal-title":"N. Engl. J. Med."},{"key":"79173_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/path.2602","volume":"219","author":"S Hallam","year":"2009","unstructured":"Hallam, S., Escorcio-Correia, M., Soper, R., Schultheiss, A. & Hagemann, T. Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB. J. Pathol. 219, 143\u2013152. https:\/\/doi.org\/10.1002\/path.2602 (2009).","journal-title":"J. Pathol."},{"key":"79173_CR5","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1084\/jem.20080108","volume":"205","author":"T Hagemann","year":"2008","unstructured":"Hagemann, T. et al. Re-educating tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 205, 1261\u20131268. https:\/\/doi.org\/10.1084\/jem.20080108 (2008).","journal-title":"J. Exp. Med."},{"key":"79173_CR6","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1200\/jco.2006.06.4642","volume":"24","author":"AM Lee","year":"2006","unstructured":"Lee, A. M. et al. Number of CD4\u2009+\u2009cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol. 24, 5052\u20135059. https:\/\/doi.org\/10.1200\/jco.2006.06.4642 (2006).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"key":"79173_CR7","doi-asserted-by":"publisher","unstructured":"Wahlin, B. E. et al. Entourage: the immune microenvironment following follicular lymphoma. Blood cancer journal 2, e52, doi: (2012). https:\/\/doi.org\/10.1038\/bcj.2011.53","DOI":"10.1038\/bcj.2011.53"},{"key":"79173_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3324\/haematol.13574","volume":"94","author":"D de Jong","year":"2009","unstructured":"de Jong, D. et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica. 94, 70\u201377. https:\/\/doi.org\/10.3324\/haematol.13574 (2009).","journal-title":"Haematologica"},{"key":"79173_CR9","doi-asserted-by":"publisher","unstructured":"Mondello, P. et al. Lack of intrafollicular memory CD4\u2009+\u2009T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood cancer J. 11 https:\/\/doi.org\/10.1038\/s41408-021-00521-4 (2021).","DOI":"10.1038\/s41408-021-00521-4"},{"key":"79173_CR10","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1200\/jco.2006.06.4766","volume":"24","author":"T Alvaro","year":"2006","unstructured":"Alvaro, T. et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol. 24, 5350\u20135357. https:\/\/doi.org\/10.1200\/jco.2006.06.4766 (2006).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"key":"79173_CR11","doi-asserted-by":"publisher","first-page":"708784","DOI":"10.3389\/fonc.2021.708784","volume":"11","author":"Y Lu","year":"2021","unstructured":"Lu, Y. et al. An Immune-Clinical Prognostic Index (ICPI) for patients with De Novo Follicular Lymphoma treated with R-CHOP\/CHOP chemotherapy. Front. Oncol. 11, 708784. https:\/\/doi.org\/10.3389\/fonc.2021.708784 (2021).","journal-title":"Front. Oncol."},{"key":"79173_CR12","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1158\/1078-0432.Ccr-11-0264","volume":"17","author":"BE Wahlin","year":"2011","unstructured":"Wahlin, B. E. et al. T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab. Clin. cancer Research: Official J. Am. Association Cancer Res. 17, 4136\u20134144. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-0264 (2011).","journal-title":"Clin. cancer Research: Official J. Am. Association Cancer Res."},{"key":"79173_CR13","doi-asserted-by":"publisher","first-page":"449","DOI":"10.7534\/j.issn.1009-2137.2017.02.025","volume":"25","author":"W Liu","year":"2017","unstructured":"Liu, W. et al. [Clinical significance of detecting CD4(+) T cells in Peripheral blood of patients with follicular lymphoma]. Zhongguo Shi Yan xue ye xue Za Zhi. 25, 449\u2013454. https:\/\/doi.org\/10.7534\/j.issn.1009-2137.2017.02.025 (2017).","journal-title":"Zhongguo Shi Yan xue ye xue Za Zhi"},{"key":"79173_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1146\/annurev-immunol-101721-061120","volume":"41","author":"A Sette","year":"2023","unstructured":"Sette, A., Sidney, J. & Crotty, S. T. Cell responses to SARS-CoV-2. Annu. Rev. Immunol. 41, 343\u2013373. https:\/\/doi.org\/10.1146\/annurev-immunol-101721-061120 (2023).","journal-title":"Annu. Rev. Immunol."},{"key":"79173_CR15","doi-asserted-by":"publisher","first-page":"12589","DOI":"10.1007\/s13277-016-5124-9","volume":"37","author":"L He","year":"2016","unstructured":"He, L. et al. Low absolute CD4(+) T cell counts in peripheral blood are associated with inferior survival in follicular lymphoma. Tumour Biology: J. Int. Soc. Oncodevelopmental Biology Med. 37, 12589\u201312595. https:\/\/doi.org\/10.1007\/s13277-016-5124-9 (2016).","journal-title":"Tumour Biology: J. Int. Soc. Oncodevelopmental Biology Med."},{"key":"79173_CR16","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/s0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel, M. J. et al. Bendamustine plus Rituximab versus CHOP plus Rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet (London England). 381, 1203\u20131210. https:\/\/doi.org\/10.1016\/s0140-6736(12)61763-2 (2013).","journal-title":"Lancet (London England)"},{"key":"79173_CR17","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3109\/10428194.2014.921298","volume":"56","author":"K Ito","year":"2015","unstructured":"Ito, K. et al. Influence of Rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma. Leuk. Lymphoma. 56, 1123\u20131125. https:\/\/doi.org\/10.3109\/10428194.2014.921298 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"79173_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3109\/10428194.2015.1110748","volume":"57","author":"A Gafter-Gvili","year":"2016","unstructured":"Gafter-Gvili, A. & Polliack, A. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk. Lymphoma. 57, 512\u2013519. https:\/\/doi.org\/10.3109\/10428194.2015.1110748 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"79173_CR19","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1200\/jco.2006.06.1648","volume":"25","author":"AM Glas","year":"2007","unstructured":"Glas, A. M. et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol. 25, 390\u2013398. https:\/\/doi.org\/10.1200\/jco.2006.06.1648 (2007).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"key":"79173_CR20","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1182\/blood-2007-11-125823","volume":"111","author":"M Taskinen","year":"2008","unstructured":"Taskinen, M., Karjalainen-Lindsberg, M. L. & Lepp\u00e4, S. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. Blood. 111, 4664\u20134667. https:\/\/doi.org\/10.1182\/blood-2007-11-125823 (2008).","journal-title":"Blood"},{"key":"79173_CR21","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/jco.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification. J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol. 32, 3059\u20133068. https:\/\/doi.org\/10.1200\/jco.2013.54.8800 (2014).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"key":"79173_CR22","doi-asserted-by":"publisher","first-page":"13471","DOI":"10.1038\/s41598-019-50029-y","volume":"9","author":"B Milcent","year":"2019","unstructured":"Milcent, B. et al. Recovery of central memory and naive peripheral T cells in Follicular Lymphoma patients receiving rituximab-chemotherapy based regimen. Sci. Rep. 9, 13471. https:\/\/doi.org\/10.1038\/s41598-019-50029-y (2019).","journal-title":"Sci. Rep."},{"key":"79173_CR23","doi-asserted-by":"publisher","first-page":"e1644110","DOI":"10.1080\/2162402x.2019.1644110","volume":"8","author":"D Simnica","year":"2019","unstructured":"Simnica, D. et al. T cell receptor next-generation sequencing reveals cancer-associated repertoire metrics and reconstitution after chemotherapy in patients with hematological and solid tumors. Oncoimmunology. 8, e1644110. https:\/\/doi.org\/10.1080\/2162402x.2019.1644110 (2019).","journal-title":"Oncoimmunology"},{"key":"79173_CR24","doi-asserted-by":"publisher","unstructured":"Batlevi, C. L. et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood cancer J. 10 https:\/\/doi.org\/10.1038\/s41408-020-00340-z (2020).","DOI":"10.1038\/s41408-020-00340-z"},{"key":"79173_CR25","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn, I. W. et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 123, 2944\u20132952. https:\/\/doi.org\/10.1182\/blood-2013-11-531327 (2014).","journal-title":"Blood"},{"key":"79173_CR26","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/jco.2017.76.8960","volume":"36","author":"W Hiddemann","year":"2018","unstructured":"Hiddemann, W. et al. Immunochemotherapy with Obinutuzumab or Rituximab for previously untreated follicular lymphoma in the GALLIUM Study: influence of Chemotherapy on Efficacy and Safety. J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol. 36, 2395\u20132404. https:\/\/doi.org\/10.1200\/jco.2017.76.8960 (2018).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"key":"79173_CR27","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.3109\/10428194.2015.1026818","volume":"56","author":"T Yutaka","year":"2015","unstructured":"Yutaka, T. et al. Sustained CD4 and CD8 lymphopenia after Rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma. Leuk. Lymphoma. 56, 3216\u20133218. https:\/\/doi.org\/10.3109\/10428194.2015.1026818 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"79173_CR28","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.leukres.2013.07.038","volume":"37","author":"D Shafer","year":"2013","unstructured":"Shafer, D. et al. Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma. Leuk. Res. 37, 1213\u20131215. https:\/\/doi.org\/10.1016\/j.leukres.2013.07.038 (2013).","journal-title":"Leuk. Res."},{"key":"79173_CR29","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s00277-020-04208-x","volume":"99","author":"HR Junl\u00e9n","year":"2020","unstructured":"Junl\u00e9n, H. R., Lockmer, S., Kimby, E. & Wahlin, B. E. Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy. Ann. Hematol. 99, 2357\u20132366. https:\/\/doi.org\/10.1007\/s00277-020-04208-x (2020).","journal-title":"Ann. Hematol."},{"key":"79173_CR30","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood.2020010263","volume":"139","author":"C Casulo","year":"2022","unstructured":"Casulo, C. et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 139, 1684\u20131693. https:\/\/doi.org\/10.1182\/blood.2020010263 (2022).","journal-title":"Blood"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79173-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79173-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79173-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T12:17:05Z","timestamp":1731673025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79173-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["79173"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-79173-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the First Affiliated Hospital of Xiamen University (2022-070), the West China Hospital of Sichuan University, and the Second Affiliated Hospital of Dalian Medical University (2024\u2009\u2212\u20091010). Written informed consent was waived by the Institutional Review Board, owing to the retrospective nature of the study. Animal studies: N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27576"}}